Autopsy report · NCT03378466

Heparin Anticoagulation in Septic Shock

“infeasible to continue due-to inability to recruit during the COVID-19 pandemic and grants coming to an end.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 3 years 10 months before it stopped.
• 178 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Manitoba

Sponsor type

University, hospital or other

Conditions

Septic Shock; Vasodilatory Shock

Interventions

Unfractionated heparin; Venous thromboprophylaxis (VTE)

Participants

178

Sites

51

Countries

Brazil, Canada, Greece, India, Pakistan, Philippines, United States

Trials that died the same way

• (mo)BETTA Trial in Transwomen for Optimization of ART
  “Lack of ability to recruit due to COVID-19 pandemic” (73% match in meaning)
• Nocturnal Nasal Continuous Positive Airway Pressure in Aspiration Pneumonia
  “Hard to recruit due to COVID-19 issue.” (71% match in meaning)
• Treating Stimulant Addiction With Repetitive Transcranial Magnetic Stimulation
  “COVID-19 pandemic adversely affected recruitment.” (71% match in meaning)
• ANTERO-5: Gastric Motility in Postoperative Ileus
  “Inadequate recruitment due to COVID-19 restrictions.” (70% match in meaning)
• An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD
  “Recruitment/enrollment ended early due to the COVID-19 pandemic” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.